高危出血患者应用吉派林抗凝血液透析疗效观察

目的：观察危重型肾功能衰竭合并高危出血患者选择抗凝药物进行血液透析治疗的效果。方法：应用吉派林(低分子肝素钠)作为抗凝剂进行血液透析。结果：129例病人进行血液透析386次，均没有出血发生。结论：吉派林在高危出血患者血液透析中使用方便，安全，效果良好。     

生长抑素治疗食管胃底静脉曲张破裂出血的临床研究

目的 探讨生长抑素治疗食管胃底静脉曲张破裂出血的临床效果。方法 应用奥曲肽治疗食管胃底静脉曲张破裂出血患者41例,并与垂体后叶素治疗的32例及三腔管治疗的25例进行对照。观察3组平均止血时间、24h止血率以及治疗前后门静脉主干直径、血流速度、血流量的变化。结果 奥曲肽治疗组、垂体后叶素治疗组、三腔管治疗组平均止血时间分别为194.27±28.88min、358.11±151.43min、134.71±32.12min,24h止血率分别为63.41％、37.50％、72％。奥曲肽治疗组止血率显著高于垂体后叶素治疗组(P<0.01)。奥曲肽治疗前后门静脉内径分别为10.86±0.41mm、13.84±0.35mm,二者有显著差异。奥曲肽治疗后其门静脉血流速度,血流量与治疗前相比较也有显著差异(P<0.01,P<0.05)。结论 奥曲肽能使门脉内径相对缩小、血流量减少和血流速度加快,从而使门脉压力降低达到止血的目的。     

冲洗液温度对前列腺切除术后出血的影响

目的 研究冲洗液温度对前列腺切除术后出血的影响。方法 耻骨上前列腺切除术患者80例,年龄60～82(平均67.4±10.3)岁,随机分为两组各40例。A组采用20℃的冲洗液冲洗膀胱,B组采用37℃的冲洗膀胱。两组所有患者均于膀胱冲洗前抽静脉血,分别测定其在20℃和37℃状态下的激活部分凝血活酶时间(APTT)、凝血酶原时间(PT)、凝血酶时间(TT)。同时比较两组术后出血量、冲洗总液量、血尿时间、寒冷反应及膀胱痉挛发生率,结果 检测80例患者血APTT,PT,TT均存在显著差异(P<0.001;冲洗总液量分别是(47883±±8953)ml和(19741±5490)mL,P<0.001;尿液转清时间分别是(47.5±16.9)h和(19.8±5.7)h,P相似文献   

Rockall危险性积分在急性上消化道出血中的应用

目的：探讨Rockall危险性积分在急性上消化道出血中的应用。方法：262例按Rockall危险性积分进行评分，并分为低危组（0～3）、中危组（4～7）、高危组（≥8）。结果：高危组与中危组相比再出血率差异无统计学意义（P〉0．05）。高危组与中危组相比死亡率明显升高（P〈0．05）。结论：Rockall危险性积分对急性上消化道出血患者的病情评估具有重要的意义。     

Surgery in Jehovah’s Witnesses

This is a retrospective study of the outcome of surgical procedures in patients who were Jehovah's Witnesses. Over a 75-month period, 58 Jehovah's Witness patients had 78 surgical procedures at the Vancouver General Hospital. Three patients had preexisting anaemia of less than 100 g.L-1 haemoglobin. Postoperative haemoglobin concentration decreased below 50 g.L-1 in three patients. One patient had a postoperative haemoglobin of 34 g.L-1 (haematocrit 10.1 per cent) and survived. One patient died from uncontrollable postoperative haemorrhage. Perioperative morbidity was not uncommon, including significant hypotension (eight cases), cardiac arrhythmias (six), myocardial ischaemia (three), excessive bleeding (four), postoperative nausea or syncope (four), and wound or urinary tract infection (four).     

海藻酸钙微胶珠的载药性能优化

利用高压静电法制备了海藻酸钙微胶珠，以牛血红蛋白作为模型药物，考察了牛血红蛋白（Hb）的稳定性、制备条件对微胶珠载药的影响。结果表明：Hb在10℃下能稳定存在，1．8％（w／v）Na-Alg与4．5％（w／v）CaCl2制备的微胶珠载药量较大，真空干燥的微胶殊彼此粘连破坏严重，冷冻干燥则表面出现明显的内陷，乙醇梯度洗脱-真空干燥球形度较好。水凝胶态的微胶珠载药后球形度完好，是理想的载药方式，24h时载药量达28．4％，为干燥后的2～3倍。     

Changes in the withdrawal bleeding pattern and endometrial histology during 17β-estradiol —dydrogesterone therapy in postmenopausal women: a 2 year prospective study

Objective: To describe changes in the withdrawal bleeding pattern and endometrial histology during a sequential 17β-estradiol —dydrogesterone regimen in postmenopausal women. Design: Open-label, non-comparative, prospective study. Setting: Gynecological outpatient department of a university hospital. Patients: Twenty-seven healthy nonhysterectomized postmenopausal women. Interventions: Continuous micronized 17β-estradiol supplementation, 2 mg daily, and cyclic administration of dydrogesterone, 10 mg daily for the first half of each 28 day treatment cycle. Main Outcome Measures: Changes in the characteristics of the withdrawal bleeding pattern and the endometrial biopsy histology during 2 years of treatment. Results: The initial withdrawal bleeding was comparable to normal menstruation with respect to amount and duration. During the 2 years of treatment the bleeding showed a significant tendency to become shorter with less blood loss. This was mainly the result of the decrease (P < 0.001) in the number of days per cycle with bleeding grade II (normal menstruation). None of the women developed endometrial hyperplasia, and in almost all women the given hormone replacement therapy regimen induced secretory or atrophic changes of the endometrium. Conclusions: This sequential 17β-estradiol —dydrogesterone regimen can be regarded as safe with respect to the prevention of endometrial disease and appeared to foster patient compliance.     

产妇抑郁对泌乳与产后流血的影响

目的：探讨产妇抑郁对泌乳与产后流血的影响。方法：对309例产妇采用自评抑郁量表评分，分成产后抑郁组和对照组，测评泌乳指标、产后流血的差异。结果：抑郁组产妇泌乳始动时间迟，产后24小时泌乳者仅13例；泌乳量少，产后72小时泌乳量多者仅13例；抑郁组产妇产后流血量多，与对照组相比差异有显著性。结论：产妇抑郁对泌乳与产后流血有不利影响，应加强对产妇进行心理健康指导。     

TNFalpha expression in hyperplastic endometrium

PROBLEM: Tumor necrosis factor-alpha (TNFalpha) is produced by the endometrium, and it has been shown that this cytokine has cyclic variations through the menstrual cycle. METHOD OF STUDY: In this study we assessed TNFalpha, estradiol and progesterone levels in the endometrium and serum of 21 patients with recent abnormal uterine bleeding (AUB). Eleven women showed histological diagnosis of endometrial hyperplasia, and ten women showed normal endometrium. RESULTS: The TNFalpha value in the serum of patients with hyperplasia and in normal endometrium did not show significant differences (64.8 +/- 21.4 vs 77.6 +/- 14.8 pg). The amounts of TNFalpha released by hyperplastic endometrial tissue were significantly higher than in control patients (258.8 +/- 78.0 vs 140.6 +/- 79.8 pg/g; P < 0.001). Immunohistochemistry of hyperplastic endometria showed a stronger staining than normal ones. Serum E2 levels in patients with hyperplastic endometrium were 49.5 +/- 31.6 ng/mL, and in controls were 107.3 +/- 66.0 ng/mL. The levels of estradiol released by hyperplastic endometria were significantly lower than in normal endometria (152.7 +/- 60.0 vs 279.9 +/- 178.7 ng/g; P < 0.003). CONCLUSIONS: Hyperplastic endometria produce higher amounts of TNFalpha with respect to controls. These findings may explain the frequent bleeding observed in the patients with endometrial hyperplasia, since TNFalpha promotes apoptosis and endometrial shedding.     

Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel: a randomized trial

BACKGROUND: This trial was conducted to compare cycle control with vaginal ring a combined contraceptive vaginal ring, and a combined oral contraceptive (COC) delivering 30 mug ethinylestradiol (EE) and 150 mug levonorgestrel. METHODS: This open-label, randomized, multi-centre, Phase III study involved adult women from 11 countries. Subjects were treated with either vaginal ring or a COC for 13 cycles (12 months). RESULTS: A total of 1030 subjects (vaginal ring, n=512; COC, n=518) comprised the intention-to-treat (ITT) population. The percentage of women in the ITT population who completed the trial was 70.9% for vaginal ring and 71.2% for the COC group. The incidence of breakthrough bleeding and spotting over cycles 2-13, the primary efficacy parameter, was lower with vaginal ring (range 2.0-6.4%) than the COC (range 3.5-12.6%), and for cycles 2 and 9 the lower incidence with vaginal ring was confirmed as statistically significant (P=0.003 and P=0.002 respectively). The incidence of intended bleeding was significantly higher over all cycles with vaginal ring (58.8-72.8%) than with the COC (43.4-57.9%). CONCLUSIONS: Cycle control with vaginal ring was excellent and superior to that of a COC containing 30 mug EE.